Medincell to Present Strategy at Jefferies Conference
Medincell announces the participation of Christophe Douat and Richard Malamut at the Jefferies London Global Healthcare Conference on November 18, 2025.
According to the press release, Christophe Douat, CEO, and Richard Malamut, Chief Medical Officer of Medincell, will present the company at the Jefferies London Global Healthcare Conference. This event is scheduled for Tuesday, November 18, 2025, at 4:00 PM GMT (5:00 PM Paris time). The presentation can be accessed live or on replay through a link provided by the company. Individual meetings with the management and business development team can also be arranged.
Company Overview
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Medincell, a biopharmaceutical company based in Montpellier, focuses on the development of long-acting injectable drugs. The company utilizes its proprietary BEPO technology to ensure controlled drug release over an extended period. The first treatment, UZEDY, aimed at treating schizophrenia, was approved by the FDA in April 2023 and is marketed in the United States by Teva. Medincell collaborates with various pharmaceutical companies to develop new treatment options.
Forward-Looking Statements
The press release reminds that certain forward-looking statements may be subject to risks and uncertainties. The company emphasizes that forecasts are based on reasonable assumptions but may vary due to uncontrollable factors. Medincell does not commit to publicly updating these statements. Readers are therefore advised not to rely solely on these anticipations for their investment decisions.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
